Literature DB >> 32234596

Multi-omics reveals the mechanisms of antidepressant-like effects of the low polarity fraction of Bupleuri Radix.

Yan Feng1, Xiaoxia Gao2, Meidai Meng1, Huanhuan Xue1, Xuemei Qin3.   

Abstract

ETHNOPHARMACOLOGICAL RELEVANCE: Radix Bupleuri (Bupleurum chinense DC.) is a traditional Chinese medicine that has the effect of soothing the liver and relieving depression, and widely used in the field of antidepression. AIM OF THE STUDY: The low polarity fraction of Bupleuri Radix (PBR) has proved to be effective for the treatment of depression based on the results of our previous study. However, mechanisms of definite antidepressant-like effects remained unclear. The purpose of this study is to reveal mechanisms of antidepressant-like effects of PBR with multi-dimensional omics.
MATERIALS AND METHODS: LC-MS metabolomics combined with 16S rRNA gene sequencing were used to investigate the effects of PBR on gut microbiota and metabolites in CUMS-induced depression, and Pearson correlation analysis was carried out on gut microbiota and metabolites.
RESULTS: PBR significantly improved depression-like behaviors in the CUMS model rats. Moreover, PBR significantly increased the levels of BDNF in the hippocampus. Cecum contents metabolomics revealed that 16 biomarkers associated with PBR antidepressant effect were screened, which were involved 3 metabolic pathways including primary bile acid biosynthesis, taurine and hypotaurine metabolism, glyoxylate and dicarboxylate metabolism. Gut microbiota further analysis demonstrated that PBR increased the diversity of gut microbiota, and significantly inhibited the growth of [Prevotella] and Ochrobactrum. Furthermore, Pearson analysis revealed there was a strong correlation between cecum contents of metabolites and gut microbiota.
CONCLUSIONS: PBR improved depression-like behavior by regulating metabolic profiles and gut microbiota, and contributing to further understand the entailed antidepressant-like mechanisms of PBR.
Copyright © 2020 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  16S rRNA gene sequencing; Antidepressant; Bupleuri radix; Gut microbiota; LC–MS; Metabolomics

Mesh:

Substances:

Year:  2020        PMID: 32234596     DOI: 10.1016/j.jep.2020.112806

Source DB:  PubMed          Journal:  J Ethnopharmacol        ISSN: 0378-8741            Impact factor:   4.360


  7 in total

Review 1.  Molecular Mechanisms Associated with Antidepressant Treatment on Major Depression.

Authors:  Lívia Ramos-da-Silva; Pamela T Carlson; Licia C Silva-Costa; Daniel Martins-de-Souza; Valéria de Almeida
Journal:  Complex Psychiatry       Date:  2021-07-09

2.  Detection of the role of intestinal flora and tryptophan metabolism involved in antidepressant-like actions of crocetin based on a multi-omics approach.

Authors:  Susu Lin; Qiaoqiao Li; Zijin Xu; Ziwei Chen; Yi Tao; Yingpeng Tong; Ting Wang; Suhong Chen; Ping Wang
Journal:  Psychopharmacology (Berl)       Date:  2022-09-28       Impact factor: 4.415

Review 3.  Research Progress on Classical Traditional Chinese Medicine Jieyu Pills in the Treatment of Depression.

Authors:  Yuan Wang; Miao Peng
Journal:  Neuropsychiatr Dis Treat       Date:  2020-12-08       Impact factor: 2.570

4.  Comparative Pharmacokinetic Study of Three Major Bioactive Components in the Normal and Different Courses of Liver-Stagnation and Spleen-Deficiency Syndrome Depressive Rats after Intragastric Administration of Zhi-Zi-Hou-Po Decoction.

Authors:  Kaiwen Luo; Mengdie Wang; Xiangxiang Pan; Yadong Xing
Journal:  J Anal Methods Chem       Date:  2022-03-24       Impact factor: 2.193

Review 5.  Efficacy and Safety of Xiaoyao Recipe in the Treatment of Poststroke Depression: A Systematic Review and Meta-Analysis.

Authors:  Dou Wang; Tao Li; Jie Ron; Meiling Mao; Yifan Yang; Yalun Feng; Yongmei Yan
Journal:  Evid Based Complement Alternat Med       Date:  2022-04-13       Impact factor: 2.650

6.  Morinda officinalis oligosaccharides mitigate chronic mild stress-induced inflammation and depression-like behaviour by deactivating the MyD88/PI3K pathway via E2F2.

Authors:  Zhen-Hua Zhu; Xu-Yuan Yin; Tu-Sun Xu; Wei-Wei Tao; Guang-Da Yao; Pei-Jie Wang; Qi Qi; Qiu-Fang Jia; Jing Wang; Yue Zhu; Li Hui
Journal:  Front Pharmacol       Date:  2022-08-16       Impact factor: 5.988

Review 7.  The three syndromes and six Chinese patent medicine study during the recovery phase of COVID-19.

Authors:  Xuedong An; Liyun Duan; Yue Hong Zhang; Shenghui Zhao; Rong Rong Zhou; Yingying Duan; Fengmei Lian; Xiaolin Tong
Journal:  Chin Med       Date:  2021-06-07       Impact factor: 5.455

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.